Evidence map›Paper›PMID 42063361›Full record

ArticleDevelopment (Cambridge, England)2026

Oscillatory co-expression of HES1 and HES5 enables a hybrid state in a cross-repressive transcription factor regulatory motif.

Veronica Biga, Anzy Miller, Anoushka Kamath, Robert Lea, Ying Q P Mak, Antony D Adamson, Elli Marinopoulou, Paul François, Nancy Papalopulu, Cerys S Manning

Abstract read
In one paragraph

Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Veronica BigaFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0001-9592-385X
Anzy MillerFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0001-6384-8795
Anoushka KamathFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0009-0000-0235-4695
Robert LeaFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0003-0522-3601
Ying Q P MakFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0009-0001-6260-8586
Antony D AdamsonGenome Editing Unit, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-5408-0013
Elli MarinopoulouFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-6379-5168
Paul FrançoisDepartment of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Quebec QC H3T 1J4, Canada.ORCID 0000-0002-2223-839X
Nancy PapalopuluFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0001-6992-6870
Cerys S ManningFaculty of Biology Medicine and Health, School of Medical Sciences, Division of Developmental Biology and Medicine, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0001-8656-5878

Funding

Medical Research Council MR/V032534/1The University of ManchesterUK Research and Innovation EP/T022000/1UKRI/Wellcome EP/T022000/1- PoLNET3a Physics of LifeWellcome Trust 201380/Z/16/ZWellcome Trust 210912/Z/18/ZWellcome Trust 224394/Z/21/Z
6 · The paper itself

Abstract

Many cell fate decisions in the developing neural tube are directed by cross-repressive transcription factor (TF) motifs that generate bistability, such that cells express one TF but not both. Hybrid states in which cells express both cross-repressing fate determinants have been observed, but how these arise or persist remains unclear. Here, we focus on HES1 and HES5, which are auto-repressive oscillatory TFs that regulate neural progenitor maintenance and are expressed in adjacent dorsoventral progenitor domains in the developing spinal cord. Knockdown experiments demonstrate that HES1 and HES5 are cross-repressing in mouse spinal cord neural progenitors, and live-cell imaging in vitro shows that they can be co-expressed, defining a hybrid state. In this state, HES proteins co-oscillate in-phase within single cells. Computational modelling indicates that modulation of cross-repression strength or relative TF abundance destabilises this state, driving resolution towards a single oscillatory HES TF. This is consistent with in vivo analysis showing transient HES1 and HES5 co-expression, followed by progressive restriction to a single TF oscillator. Our findings suggest that oscillatory expression enables the co-existence of cross-repressing TFs, allowing hybrid states within a developmental bistable motif.

Indexed as

Basic Helix-Loop-Helix ProteinsGene Expression Regulation, DevelopmentalHomeodomain ProteinsRepressor ProteinsTranscription FactorsAnimalsMiceNeural Stem CellsSpinal CordTranscription Factor HES-1Basic Helix-Loop-Helix ProteinsHes1 protein, mouseHes5 protein, mouseHomeodomain ProteinsRepressor ProteinsTranscription Factor HES-1Transcription FactorsCross-repressing transcription factorsOscillatory dynamicsTranscription factor regulation

Identifiers

PMID42063361
PMCPMC13286377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.